Business
A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
- Published
- (2 h ago)
- Outlet
- CNBC Top News
- Section
- Business
- Length here
- Headline and 20-word snippet. The full article is at the source.
More from CNBC Top News and around the same time
Iran claims four tankers struck mines in Hormuz as strike fears grow after U.S. midtermsHormuz mine claims, Houthi attacks raise fears of renewed strikes as the U.S. reportedly weighs a fresh military campaign after midterm elections.Israel faces weeks of coalition haggling as Netanyahu’s party claims election 'stolen'Israel's election leaves the country facing weeks of coalition bargaining and an uphill battle for the opposition party to form a majority government.BOJ holds rates as inflation aligns with 2% target for first time since 2013The BOJ declared that its underlying inflation target of 2% has been met, the first time the central bank has done so since it set the target in 2013.Intel plunges on a major guidance miss. What went wrong — and how to proceedFurther downside is certainly possible, but selling now won't erase the losses we've taken.Microsoft plans to raise $25 billion in debt as it pursues AI buildoutMicrosoft boasts a strong credit rating and has managed to maintain positive free cash flow, unlike Meta, Alphabet and Amazon.How elections worldwide are testing Trump’s influence abroadRecent election losses by leaders linked to Trump have prompted questions about whether his influence over the global right is weakening.This page holds the headline and a short snippet as published by CNBC Top News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
